We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
Our principal executive offices are located at 360 N Pastoria Avenue, Sunnyvale, California, and our telephone number is (800) 436-0826.
We were initially incorporated under the laws of State of Delaware in 2014 under the name Brain Stethoscope, Inc. We changed our name to CeriBell, Inc. in 2015.
Our ticker is CBLL and it is traded on the NASDAQ exchange.
Ceribell does not currently have a direct stock purchase plan.
Quarterly and annual reports, as well as other SEC filings, can be accessed on the SEC Filings portion of our Investor Relations website or directly from the SEC at www.sec.gov.
Our fiscal year end is December 31.
We do not intend to pay cash dividends on our common stock, as we intend to retain all available funds and any future earnings to support operations and finance the growth and development of our business.
Our independent registered public accountants are PricewaterhouseCoopers LLP.
We use Broadridge Corporate Issuer Solutions, Inc.
Broadridge Corporate Issuer Solutions, LLC
1155 Long Island Avenue
Edgewood, NY 11717
1–877–830–4932
www.broadridge.com
You can view our management team and members of our Board of Directors by visiting the About Us section of our website.
We will issue press releases that include the date of our quarterly earnings calls periodically. When the release is issued, call details and webcast links will be posted on the Events section of our website.
You can view our latest press releases, including our quarterly financial releases, on the News section of our website.
You can contact Ceribell Investor Relations via email at: investors@ceribell.com.
If your shares are held in street name (by your broker), you must notify the securities firm holding your stock. If you hold shares in your name, you may reach our transfer agent at the address or phone numbers below or by visiting www.shareholder.broadridge.com
Broadridge Corporate Issuer Solutions, LLC
51 Mercedes Way
Attn: IWS
Edgewood, NY 11717
1-844-998-0339
www.shareholder.broadridge.com